KR20210073957A - Cosmetic composition for stabilizing poorly soluble materials - Google Patents

Cosmetic composition for stabilizing poorly soluble materials Download PDF

Info

Publication number
KR20210073957A
KR20210073957A KR1020190164798A KR20190164798A KR20210073957A KR 20210073957 A KR20210073957 A KR 20210073957A KR 1020190164798 A KR1020190164798 A KR 1020190164798A KR 20190164798 A KR20190164798 A KR 20190164798A KR 20210073957 A KR20210073957 A KR 20210073957A
Authority
KR
South Korea
Prior art keywords
block
weight
cosmetic composition
alcohol
surfactant
Prior art date
Application number
KR1020190164798A
Other languages
Korean (ko)
Other versions
KR102294985B1 (en
KR102294985B9 (en
Inventor
홍성윤
이준배
박명삼
Original Assignee
코스맥스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76329417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20210073957(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 코스맥스 주식회사 filed Critical 코스맥스 주식회사
Priority to KR1020190164798A priority Critical patent/KR102294985B1/en
Priority to PCT/KR2020/014419 priority patent/WO2021118044A1/en
Publication of KR20210073957A publication Critical patent/KR20210073957A/en
Priority to KR1020210106951A priority patent/KR102322172B1/en
Priority to KR1020210110343A priority patent/KR102322173B1/en
Application granted granted Critical
Publication of KR102294985B1 publication Critical patent/KR102294985B1/en
Publication of KR102294985B9 publication Critical patent/KR102294985B9/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/342Alcohols having more than seven atoms in an unbroken chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0295Liquid crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • A61K8/553Phospholipids, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • A61K8/675Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/596Mixtures of surface active compounds

Abstract

The present invention relates to a cosmetic composition for stabilizing poorly soluble substances, wherein the cosmetic composition comprises poorly soluble substances, fatty alcohols, surfactants and auxiliary surfactants.

Description

난용성 물질의 안정화용 화장료 조성물 {Cosmetic composition for stabilizing poorly soluble materials}Cosmetic composition for stabilizing poorly soluble materials {Cosmetic composition for stabilizing poorly soluble materials}

난용성 물질, 지방 알코올, 계면활성제, 및 보조 계면활성제를 포함하는 난용성 물질을 제형 내 안정화시키는 화장료 조성물에 관한 것이다.It relates to a cosmetic composition for stabilizing a sparingly soluble substance in a formulation including a sparingly soluble substance, a fatty alcohol, a surfactant, and an auxiliary surfactant.

센텔라아시아티카는 아시아티코사이드(Asiaticoside), 마데카식애씨드(Madecassic acid), 아시아틱애씨드(Asiatic acid) 등으로 구성되어 있으며, Advances in Dermatology and Allergology, 2013, 30(1), 46-49 및 Journal of Coastal Life Medicine, 2016, 4(12), 1000-1007 등에 의하면, 상처치유, 피부진정, 보습, 피부장벽개선, 각질개선, 주름개선, 콜라겐 합성 등에 효과가 있는 것으로 알려져 있다. 이에 피부 진정효과 등 용도로 사용하기 위한 다양한 연구가 진행되고 있으나, 센텔라아시아티카는 물, 오일류에 대하여 난용성 물질로 제품화가 매우 어려운 물질이다.Centella asiatica consists of Asiaticoside, Madecassic acid, Asiatic acid, etc., Advances in Dermatology and Allergology, 2013, 30(1), 46-49 and According to Journal of Coastal Life Medicine, 2016, 4(12), 1000-1007, etc., it is known to be effective in wound healing, skin soothing, moisturizing, skin barrier improvement, keratin improvement, wrinkle improvement, collagen synthesis, etc. Therefore, various studies are being conducted to use it for purposes such as skin soothing effect, but Centella asiatica is a material that is very difficult to commercialize as it is poorly soluble in water and oil.

등록특허 10-0904370에 따르면, 항균용 화장료 조성물로 센텔라아시아티카를 함유한 나노리포좀에 대한 제조기술이 소개되었으나, 그 함량이 매우 낮고(0.01%), 기피용매인 에탄올을 사용하는 등 최근 트렌드와 격차가 있는 문제가 있다. 또한, 등록특허 10-1984192에 따르면, 양친매성 고분자를 이용하여 코어-쉘 캡슐로 안정화한 기술이 소개되었으나, 일부 에탄올 및 수분의 회전 증발과정이 필요하여 공정이 매우 복잡하여 제품화가 용이하지 않은 문제가 있다. 또한, 등록특허 10-1509579에 따르면, 온도 감응성 고분자 및 비수계 액정상을 이용한 제조기술이 소개되었으나, 액정상 제조 후 냉각, 후첨과정이 필요하고, 아지믹서와 패들믹서가 필요하는 등 그 제조과정이 복잡하고 제조시간이 많이 소비되는 등의 문제가 있다. According to registered patent 10-0904370, a manufacturing technology for nanoliposomes containing Centella asiatica as an antibacterial cosmetic composition was introduced, but the content is very low (0.01%), and recent trends such as using ethanol, a repellent solvent, are used. There is a problem with the gap. In addition, according to Patent Registration 10-1984192, a technique of stabilizing a core-shell capsule using an amphiphilic polymer was introduced, but a rotary evaporation process of some ethanol and water is required, so the process is very complicated and not easy to commercialize there is In addition, according to Patent No. 10-1509579, a manufacturing technology using a temperature-sensitive polymer and a non-aqueous liquid crystal phase has been introduced, but cooling and post-addition processes are required after the liquid crystal phase is manufactured, and an azimuth mixer and a paddle mixer are required. There is a problem such as this complexity and a lot of manufacturing time is consumed.

이러한 배경 하에, 본 발명자들은 지방 알코올, 스테아레이트계 계면활성제, 글루코사이드계 계면활성제, 소르비탄계 계면활성제, 및 보조 계면활성제를 이용하여 난용성 물질을 화장료 조성형 내의 제형 안정성을 극대화시킬 수 있음을 확인하였다.Under this background, the present inventors confirmed that it is possible to maximize formulation stability of poorly soluble substances in the cosmetic composition type using fatty alcohols, stearate-based surfactants, glucoside-based surfactants, sorbitan-based surfactants, and auxiliary surfactants. did.

일 양상은 난용성 물질, 지방 알코올, 계면활성제, 및 보조 계면활성제를 포함하는 난용성 물질의 안정화용 화장료 조성물을 제공한다.One aspect provides a cosmetic composition for stabilizing a sparingly soluble substance comprising a sparingly soluble substance, a fatty alcohol, a surfactant, and an auxiliary surfactant.

일 양상은 난용성 물질, 지방 알코올, 계면활성제, 및 보조 계면활성제를 포함하는 난용성 물질의 안정화용 화장료 조성물을 제공한다.One aspect provides a cosmetic composition for stabilizing a sparingly soluble substance comprising a sparingly soluble substance, a fatty alcohol, a surfactant, and an auxiliary surfactant.

상기 화장료 조성물의 유효성분인 지방 알코올, 계면활성제, 및 보조 계면활성제는 난용성 물질을 포함한 화장료 조성물을 상온, 고온, 또는 냉동에서 장기 보관하더라도 입도 변화, 점도 변화, 난용성 물질의 석출 현상을 나타내지 않고, 조성물의 광택 정도를 유지할 수 있으며, 특히, 냉동 장기 보관 후에도 구조의 변화 없이 피부 모사 구조를 유지하는데 도움을 줄 수 있다.Fatty alcohol, surfactant, and auxiliary surfactant, which are active ingredients of the cosmetic composition, exhibit particle size change, viscosity change, and precipitation of poorly soluble substances even when the cosmetic composition containing the poorly soluble substance is stored at room temperature, high temperature, or frozen for a long time. It is possible to maintain the gloss level of the composition, and in particular, it can help to maintain the skin mimic structure without changing the structure even after long-term storage in the refrigerator.

상기 난용성 물질은 센텔라아시아티카일 수 있다. 상기 센텔라아시아티카는 마데카식 애씨드(Madecassic acid), 아시아틱 애씨드(Asiatic acid), 아시아티코사이드(Asiaticoside), 마데카소사이드(Madecassocide) 등을 일정 비율로 포함하며, 물과 오일에 거의 불용인 백색내지 미황색 고체이다. 또한, 센텔라아시아티카는 콜라겐 합성 증진, 상처 치유, 섬유아세포 증식 촉진, 광노화 완화 등에 효능이 있는 것으로 알려져 있다(Advances in Dermatology and Allergology, 2013, 30(1), 46-49).The sparingly soluble material may be Centella asiatica. The Centella asiatica contains madecassic acid, asiatic acid, asiaticoside, madecassocide, etc. in a certain ratio, and is almost insoluble in water and oil. It is a white to pale yellow solid. In addition, Centella asiatica is known to be effective in promoting collagen synthesis, wound healing, promoting fibroblast proliferation, and alleviating photoaging (Advances in Dermatology and Allergology, 2013, 30(1), 46-49).

상기 난용성 물질은 조성물 총 중량에 대하여 0.001 내지 20 중량%, 예를 들어 0.001 내지 18 중량%, 예를 들어 0.001 내지 16 중량%, 예를 들어 0.001 내지 14 중량%, 예를 들어 0.001 내지 12 중량%, 예를 들어 0.001 내지 10 중량%, 예를 들어 0.001 내지 9 중량%, 예를 들어 0.001 내지 8 중량%, 예를 들어 0.001 내지 7 중량%, 예를 들어 0.001 내지 6 중량%, 예를 들어 0.001 내지 5 중량%, 예를 들어 0.001 내지 4 중량%, 예를 들어 0.001 내지 3 중량%, 예를 들어 0.001 내지 2 중량%로 포함될 수 있다.The sparingly soluble substance is 0.001 to 20% by weight, for example 0.001 to 18% by weight, for example 0.001 to 16% by weight, for example 0.001 to 14% by weight, for example 0.001 to 12% by weight based on the total weight of the composition %, for example 0.001 to 10% by weight, for example 0.001 to 9% by weight, for example 0.001 to 8% by weight, for example 0.001 to 7% by weight, for example 0.001 to 6% by weight, for example It may be included in an amount of 0.001 to 5% by weight, for example, 0.001 to 4% by weight, for example, 0.001 to 3% by weight, for example, 0.001 to 2% by weight.

상기 지방 알코올은 일반적으로 고분자량의 곧은-사슬 제1급 알코올을 의미하는 것으로, 긴-사슬 알코올(long-chain alcohol)과 혼용될 수 있다. 예를 들어, 상기 지방 알코올은 스테아릴 알코올, 세틸 알코올, 세테아릴 알코올, 미리스틸 알코올, 카프릴릭 알코올, 라우릴 알코올, 데실 알코올, 올레일 알코올, 또는 이들의 조합일 수 있다.The fatty alcohol generally refers to a high molecular weight straight-chain primary alcohol, and may be used interchangeably with a long-chain alcohol. For example, the fatty alcohol may be stearyl alcohol, cetyl alcohol, cetearyl alcohol, myristyl alcohol, caprylic alcohol, lauryl alcohol, decyl alcohol, oleyl alcohol, or a combination thereof.

상기 지방 알코올은 조성물 총 중량에 대하여 0.1 내지 20 중량%, 예를 들어 0.1 내지 18 중량%, 예를 들어 0.1 내지 16 중량%, 예를 들어 0.1 내지 14 중량%, 예를 들어 0.1 내지 12 중량%, 예를 들어 0.1 내지 10 중량%, 예를 들어 0.1 내지 9 중량%, 예를 들어 0.1 내지 8 중량%, 예를 들어 0.1 내지 7 중량%, 예를 들어 0.1 내지 6 중량%, 예를 들어 1 내지 10 중량%, 예를 들어 1 내지 9 중량%, 예를 들어 1 내지 8 중량%, 예를 들어 1 내지 7 중량%, 예를 들어 1 내지 6 중량%로 포함될 수 있다.The fatty alcohol may be present in an amount of 0.1 to 20% by weight, for example 0.1 to 18% by weight, for example 0.1 to 16% by weight, for example 0.1 to 14% by weight, for example 0.1 to 12% by weight, based on the total weight of the composition. , for example 0.1 to 10% by weight, for example 0.1 to 9% by weight, for example 0.1 to 8% by weight, for example 0.1 to 7% by weight, for example 0.1 to 6% by weight, for example 1 to 10% by weight, for example 1 to 9% by weight, for example 1 to 8% by weight, for example 1 to 7% by weight, for example 1 to 6% by weight.

상기 계면활성제는 스테아레이트계 계면활성제, 글루코사이드계 계면활성제, 소르비탄계 계면활성제, 또는 이들의 조합일 수 있다. 상기 계면활성제는 폴리글리세린지방산에스테르류, 소르비탄지방산에스테르류, 폴리옥시에틸렌지방산에스테르류, 폴리옥시에틸렌소르비탄지방산에스테르류, 폴리옥시에틸렌알킬에테르류, 야자유지방산모노에탄올아미드, 폴리옥 시에틸렌 경화 피마자유, 라우릴황산나트륨, 피로글루타민산이소스테아린산폴리옥시에틸렌글리세릴, 알킬벤젠술 폰산나트륨, 폴리옥시에틸렌스테아릴에테르, 디알킬술포숙신산, 브롬화세틸피리디늄, 염화-n-옥타데실트리메틸 암모늄, 모노알킬인산, N-아실술타민산, N-아실글루타민, 자당 지방산 에스테르, 폴리옥시에틸렌소르비탄모노스테아레이트, 폴리옥시에틸렌라우릴에테르황산나트륨, 폴리옥시에틸렌 환원 라놀린, 슈거에스테르 등일 수 있다. The surfactant may be a stearate-based surfactant, a glucoside-based surfactant, a sorbitan-based surfactant, or a combination thereof. The surfactant is polyglycerol fatty acid esters, sorbitan fatty acid esters, polyoxyethylene fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, palm oil fatty acid monoethanolamide, polyoxyethylene cured Castor oil, sodium lauryl sulfate, polyoxyethylene glyceryl pyroglutamic isostearate, sodium alkylbenzenesulfonate, polyoxyethylene stearyl ether, dialkylsulfosuccinic acid, cetylpyridinium bromide, -n-octadecyltrimethyl ammonium chloride, mono alkyl phosphoric acid, N-acyl sultamic acid, N-acyl glutamine, sucrose fatty acid ester, polyoxyethylene sorbitan monostearate, sodium polyoxyethylene lauryl ether sulfate, polyoxyethylene reduced lanolin, sugar ester, and the like.

예를 들어, 상기 스테아레이트계 계면활성제는 글리세릴스테아레이트, 글리세린모노스테아레이트, 티이에이스테아레이트, 폴리옥시에틸렌(30)-디폴리히드록시스테아레이트, 폴리글리세릴 3-디폴리히드록시스테아레이트, 이소스테아릴이소스테아레이트, 폴리글리세릴-2-테트라이소스테아레이트, 폴리글리세릴-2-트리이소스테아레이트, 폴리글리세릴-4-이소스테아레이트, PEG-20-스테아레이트, PEG-40-스테아레이트, PEG-100-스테아레이트, 수크로오스스테아레이트 또는 이들의 조합일 수 있다. 예를 들어, 상기 글루코사이드계 계면활성제는 세테아릴 글루코사이드, 데실 글루코사이드, 코코-글루코사이드, 베헤닐알코올, 아라키딜알코올, 아라키딜글루코사이드, C10-20 알킬 글루코사이드, 또는 이들의 조합일 수 있다. 예를 들어, 상기 소르비탄계 계면활성제는 소르비탄라우레이트, 소르비탄스테아레이트, 소르비탄올리에이트, 소르비탄세스퀘올리에이트, 소르비탄트라이스테아레이트, 소르비탄팔미테이트, 소르비탄트라이올리에이트, 또는 이들의 조합일 수 있다.For example, the stearate-based surfactants include glyceryl stearate, glycerin monostearate, TE stearate, polyoxyethylene (30)-dipolyhydroxystearate, and polyglyceryl 3-dipolyhydroxystearate. Late, isostearylisostearate, polyglyceryl-2-tetraisostearate, polyglyceryl-2-triisostearate, polyglyceryl-4-isostearate, PEG-20-stearate, PEG -40-stearate, PEG-100-stearate, sucrose stearate, or a combination thereof. For example, the glucoside-based surfactant may be cetearyl glucoside, decyl glucoside, coco-glucoside, behenyl alcohol, arachidyl alcohol, arachidyl glucoside, C10-20 alkyl glucoside, or a combination thereof. For example, the sorbitan-based surfactant is sorbitan laurate, sorbitan stearate, sorbitan oleate, sorbitan sesqueoleate, sorbitan tristearate, sorbitan palmitate, sorbitan trioleate, or a combination thereof.

상기 계면활성제는 조성물 총 중량에 대하여 0.1 내지 20 중량%, 예를 들어 0.1 내지 18 중량%, 예를 들어 0.1 내지 16 중량%, 예를 들어 0.1 내지 14 중량%, 예를 들어 0.1 내지 12 중량%, 예를 들어 0.1 내지 10 중량%, 예를 들어 0.1 내지 9 중량%, 예를 들어 0.1 내지 8 중량%, 예를 들어 0.1 내지 7 중량%, 예를 들어 0.1 내지 6 중량%, 예를 들어 0.1 내지 5 중량%, 예를 들어 1 내지 10 중량%, 예를 들어 1 내지 9 중량%, 예를 들어 1 내지 8 중량%, 예를 들어 1 내지 7 중량%, 예를 들어 1 내지 6 중량%, 예를 들어 1 내지 5 중량%로 포함될 수 있다.The surfactant is present in an amount of 0.1 to 20% by weight, for example 0.1 to 18% by weight, for example 0.1 to 16% by weight, for example 0.1 to 14% by weight, for example 0.1 to 12% by weight, based on the total weight of the composition. , for example 0.1 to 10% by weight, for example 0.1 to 9% by weight, for example 0.1 to 8% by weight, for example 0.1 to 7% by weight, for example 0.1 to 6% by weight, for example 0.1 to 5% by weight, such as 1 to 10% by weight, such as 1 to 9% by weight, such as 1 to 8% by weight, such as 1 to 7% by weight, such as 1 to 6% by weight; For example, it may be included in 1 to 5% by weight.

상기 보조 계면활성제는 나이아신아미드(Niacinamide), 우레아(Urea), N,N-디에틸니코틴아미드(N,N-diethylnicotinamide) 등과 같은 단분자 물질; 폴리에틸렌글리콜-블록-폴리프로필렌글리콜(PEG-b-PPG), 폴리카프로락톤-블록-폴리에틸렌글리콜(PCL-b-PEG), 폴리프로필렌글리콜-블록-폴리카프로락톤(PPG-b-PCL) 등과 같은 이중 블록 공중합체; 또는 폴리에틸렌글리콜-블록-폴리프로필렌글리콜-블록-폴리에틸렌글리콜(PEG-b-PPG-b-PEG), 폴리에틸렌글리콜-블록-폴리카프로락톤-블록-폴리에틸렌글리콜(PEG-b-PCL-b-PEG), 폴리카프로락톤-블록-폴리에틸렌글리콜-블록-폴리카프로락톤(PCL-b-PEG-b-PCL), 폴리프로필렌글리콜-블록-폴리카프로락톤-블록-폴리프로필렌글리콜(PPG-b-PCL-b-PPG), 폴리카프로락톤-블록-폴리프로필렌글리콜-블록폴리카프로락톤(PCL-b-PPG-b-PCL) 등과 같은 삼중 블록 공중합체; 또는 이들의 조합일 수 있다.The auxiliary surfactant is a monomolecular substance such as niacinamide (Niacinamide), urea (Urea), N,N- diethylnicotinamide (N,N-diethylnicotinamide) and the like; such as polyethylene glycol-block-polypropylene glycol (PEG-b-PPG), polycaprolactone-block-polyethylene glycol (PCL-b-PEG), polypropylene glycol-block-polycaprolactone (PPG-b-PCL), etc. double block copolymer; or polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol (PEG-b-PPG-b-PEG), polyethylene glycol-block-polycaprolactone-block-polyethylene glycol (PEG-b-PCL-b-PEG) , polycaprolactone-block-polyethylene glycol-block-polycaprolactone (PCL-b-PEG-b-PCL), polypropylene glycol-block-polycaprolactone-block-polypropylene glycol (PPG-b-PCL-b -PPG), polycaprolactone-block-polypropylene glycol-block polycaprolactone (PCL-b-PPG-b-PCL), etc.; or a combination thereof.

상기 보조 계면활성제는 조성물 총 중량에 대하여 0.1 내지 10 중량%, 예를 들어 0.1 내지 9 중량%, 예를 들어 0.1 내지 8 중량%, 예를 들어 0.1 내지 7 중량%, 예를 들어 0.1 내지 6 중량%, 예를 들어 0.1 내지 5 중량%, 예를 들어 1 내지 10 중량%, 예를 들어 1 내지 9 중량%, 예를 들어 1 내지 8 중량%, 예를 들어 1 내지 7 중량%, 예를 들어 1 내지 6 중량%, 예를 들어 1 내지 5 중량%로 포함될 수 있다.The auxiliary surfactant is 0.1 to 10% by weight, for example 0.1 to 9% by weight, for example 0.1 to 8% by weight, for example 0.1 to 7% by weight, for example 0.1 to 6% by weight relative to the total weight of the composition %, such as 0.1 to 5% by weight, such as 1 to 10% by weight, such as 1 to 9% by weight, such as 1 to 8% by weight, such as 1 to 7% by weight, such as 1 to 6% by weight, for example, may be included in 1 to 5% by weight.

일구체예에 있어서, 난용성 물질로서 센텔라아시아티카; 지방 알코올로서 세테아릴 알코올, C14-22 알코올; 계면활성제로서 글리세릴 스테아레이트, PEG 100-스테아레이트, 알킬 글루코사이드, 하이드로제네이트 레시틴; 보조 계면활성제로서 나이아신아미드를 포함하는 화장료 조성물을 제조하고, 상기 화장료 조성물은 제조 직후, 상온, 고온, 냉동에서 12주 보관 후의 입도 및 점도 분포를 측정한 결과, 입도 및 점도 변화율이 1 내지 10%로서, 장기 보관시에도 우수한 제형 안정성을 유지함을 확인하였다. In one embodiment, Centella asiatica as a sparingly soluble substance; cetearyl alcohol, C14-22 alcohol as fatty alcohol; glyceryl stearate, PEG 100-stearate, alkyl glucoside, hydrogenate lecithin as surfactants; A cosmetic composition containing niacinamide as an auxiliary surfactant was prepared, and as a result of measuring the particle size and viscosity distribution after 12 weeks of storage at room temperature, high temperature, and freezing, immediately after the preparation, the cosmetic composition had a particle size and viscosity change rate of 1 to 10% As a result, it was confirmed that excellent formulation stability was maintained even during long-term storage.

일구체예에 있어서, 상기 화장료 조성물의 피부 모사 구조를 편광 현미경을 이용하여 관찰하고, X선 산란법으로 분석한 결과, 상기 화장료 조성물은 다층 라멜라 구조를 갖는 액정 에멀젼 제형이고, 장기 보관시에도 다층 라멜라 구조를 유지할 수 있음을 확인하였다.In one embodiment, the skin-mimicking structure of the cosmetic composition was observed using a polarization microscope, and as a result of analysis by X-ray scattering, the cosmetic composition is a liquid crystal emulsion formulation having a multi-layered lamellar structure, and multi-layered even during long-term storage It was confirmed that the lamellar structure could be maintained.

상기 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 구체적으로는 상기 화장료 조성물은 다층 라멜라 구조를 갖는 액정 에멀젼 제형일 수 있다. 상기 용어 "액정"이란 고체와 액체의 중간 상태를 일컫는 용어로서, 대개 친수성 부분과 친유성 부분을 동시에 가지고 있는 유기 분자들이 친수성 부분과 친유성 부분으로 일정하게 배열하여 여러 층을 이루고 있는 라멜라 구조가 생성되는 계(system)를 의미할 수 있다. 액정은 액체와 고체의 특성을 모두 가지고 있어, 점도와 유동성 측면에서는 액체의 특성을 보이고, 빛의 산란과 반사와 같은 물성에 있어서는 고체의 특성을 나타내는 고유한 성질을 가지고 있어 화장품, 의약품, 식품 및 전자공업 등의 분야에서 그 응용범위가 넓은 것으로 알려져 있다. 특히, 화장품 분야에서 액정은 유화물의 제조 시 계면에서 형성되어 유화물의 안정성을 높이고, 유화계 내에서 팽윤을 일으켜 크림이나 유액의 점도와 경도를 높이는 작용을 한다.The cosmetic composition may be prepared in any formulation conventionally prepared in the art, and specifically, the cosmetic composition may be a liquid crystal emulsion formulation having a multilayer lamellar structure. The term "liquid crystal" is a term that refers to an intermediate state between a solid and a liquid, and usually has a lamellar structure in which organic molecules having both a hydrophilic part and a lipophilic part are uniformly arranged into a hydrophilic part and a lipophilic part to form several layers. It may mean a generated system. Liquid crystal has both liquid and solid properties, so it shows liquid properties in terms of viscosity and fluidity, and has unique properties that show properties of a solid in terms of physical properties such as light scattering and reflection. It is known that its application range is wide in fields such as the electronics industry. In particular, in the cosmetic field, liquid crystal is formed at the interface during the manufacture of an emulsion to increase the stability of the emulsion, and causes swelling in the emulsion system to increase the viscosity and hardness of the cream or emulsion.

상기 액정 화장료 조성물은 종래 화장품 기술분야에서 알려진 액정 유화기술로 제조될 수 있다. 예를 들어, 상기 액정 화장료 조성물은 온도에 따라 변화되는 써모트로픽 액정(Thermotropic liquid crystal) 또는 조성의 변화에 따라 변화되는 리오트로픽 액정(Lyotropic liquid crystal)도 될 수 있으며, 이중에서 리오트로픽 액정은 예컨대, 세테아릴알코올, 스테아릴알코올 등과 같은 지방 알코올을 사용하는 방법, 콜레스테롤, 콜레스테릴미리스테이트나 세라마이드를 사용하는 방법, 또는 레시틴과 같은 인지질을 사용하는 방법이 사용될 수 있다.The liquid crystal cosmetic composition may be prepared by a liquid crystal emulsification technique known in the art of conventional cosmetics. For example, the liquid crystal cosmetic composition may be a thermotropic liquid crystal that changes with temperature or a lyotropic liquid crystal that changes with a change in composition, among which the lyotropic liquid crystal is, for example, , a method using a fatty alcohol such as cetearyl alcohol or stearyl alcohol, a method using cholesterol, cholesteryl myristate or ceramide, or a method using a phospholipid such as lecithin may be used.

일구체예에 있어서, 상기 액정 에멀젼 제형의 화장료 조성물은 계면활성제, 오일을 혼합하고 70~80 ℃에서 가온 용해시켜 유상부를 제조하는 단계; 폴리올 및 기타 수용성 물질과 난용성 물질(예를 들어, 센텔라아시아티카)을 물에 70~80 ℃에서 가온 용해시켜 수상부를 제조하는 단계; 상기 유상부를 상기 수상부에 첨가한 후 보존제를 더 첨가하여 교반하는 단계; 및 상기 교반 후 약 30 ℃까지 급속 냉각한 후 반응물을 탈포기로 탈포하는 단계를 포함하는 제조방법에 의해 제조될 수 있다.In one embodiment, the cosmetic composition of the liquid crystal emulsion formulation comprises the steps of: preparing an oil phase by mixing a surfactant and an oil and dissolving by heating at 70 to 80 ° C; preparing an aqueous phase by heating and dissolving polyol and other water-soluble substances and poorly soluble substances (eg, Centella asiatica) in water at 70-80° C.; After adding the oil phase to the aqueous phase, further adding a preservative and stirring; And it may be prepared by a manufacturing method comprising the step of rapidly cooling to about 30 ℃ after the stirring and then defoaming the reactant with a deaerator.

상기 화장료 조성물은 필요에 따라 산화방지제, 방부제, pH 조절제, 보습제, 윤활제 등의 성분을 더 첨가할 수 있다. 또한, 상기 화장료 조성물은 피부에 필수 영양소를 보조적으로 제공할 수 있는 물질을 추가로 포함하는데, 바람직하게는 천연향, 화장품향, 또는 식물추출물이 포함되지만 이들에 국한되지 않는 보조제를 함유할 수 있다.The cosmetic composition may further add components such as antioxidants, preservatives, pH adjusters, humectants, and lubricants as necessary. In addition, the cosmetic   composition further includes a substance capable of providing essential nutrients to the skin auxiliary, preferably, a natural fragrance,   cosmetic fragrance, or an auxiliary agent including but not limited to plant extracts. It may contain. .

일 양상에 따른 화장료 조성물은 지방 알코올, 계면활성제, 보조 계면활성제를 포함함으로써 상온, 저온 또는 고온 보관 시에도 난용성 물질인 센텔라아시아티카의 제형 내 안정성을 유지하여, 피부 진정, 보습, 상처 치유, 콜라겐 합성 등의 효과를 극대화시킬 수 있다. The cosmetic composition according to an aspect maintains the stability in the formulation of Centella asiatica, a poorly soluble material, even when stored at room temperature, low temperature or high temperature by including fatty alcohol, surfactant, and auxiliary surfactant, thereby soothing the skin, moisturizing, and healing wounds. , collagen synthesis, etc. can be maximized.

일 양상에 따른 화장료 조성물은 난용성 물질인 센텔라아시아티카를 피부 친화적인 다중 라멜라 액정 제형에 함유함으로써, 석출 현상이 발생하지 않도록 할 수 있다.The cosmetic composition according to an aspect contains Centella asiatica, a sparingly soluble material, in a skin-friendly multi-lamellar liquid crystal formulation, so that precipitation does not occur.

도 1은 비교예 1 및 실시예 1 조성물의 제조 직후와 냉동 12주 보관 후의 입도 분포도를 나타낸 그래프이다.
도 2는 실시예 1 조성물의 제조 직후 및 냉동 12주 보관 후의 피부 모사 구조를 편광현미경으로 관찰한 이미지이다.
도 3은 실시예 1 조성물의 제조 직후 및 냉동 12주 보관 후의 라멜라 층상 구조를 소각 X선 산란법(SAXS)으로 분석한 그래프이다.
1 is a graph showing the particle size distribution immediately after preparation of the compositions of Comparative Examples 1 and 1 and after freezing for 12 weeks.
Figure 2 is an image observed with a polarizing microscope immediately after the preparation of the composition of Example 1 and after 12 weeks of freezing and storage of the skin mimicking structure.
3 is a graph analyzed by small-angle X-ray scattering (SAXS) of the lamellar layer structure immediately after preparation of the composition of Example 1 and after freezing for 12 weeks.

이하 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, it will be described in more detail through examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

비교예 1, 및 실시예 1 내지 4. 난용성 물질을 함유한 일반 수중유 에멀젼, 및 액정 에멀젼의 제조Comparative Example 1 and Examples 1 to 4. Preparation of general oil-in-water emulsion containing poorly soluble substances, and liquid crystal emulsion

난용성 물질인 센텔라아시아티카를 함유한 비교예 1의 일반 수중유 에멀젼과 실시예 1 내지 4의 액정 에멀젼을 제조하였다. 비교예 1 및 실시예 1 내지 4의 구체적인 조성은 하기 표 1에 나타내었다. A general oil-in-water emulsion of Comparative Example 1 and liquid crystal emulsions of Examples 1 to 4 containing Centella asiatica, a poorly soluble substance, were prepared. Specific compositions of Comparative Example 1 and Examples 1 to 4 are shown in Table 1 below.

성분ingredient 비교예 1Comparative Example 1 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4 1. D.I. water1. D.I. water To 100To 100 To 100To 100 To 100To 100 To 100To 100 To 100To 100 2. Glycerin2. Glycerin 2.002.00 2.002.00 2.002.00 2.002.00 2.002.00 3. Butylene glycol3. Butylene glycol 5.005.00 5.005.00 5.005.00 5.005.00 5.005.00 4. Dipropylene glycol4. Dipropylene glycol 10.010.0 10.010.0 10.010.0 10.010.0 10.010.0 5. Triethanol amine5. Triethanolamine 0.100.10 0.100.10 0.100.10 0.100.10 0.100.10 6. EDTA-2Na6. EDTA-2Na 0.020.02 0.020.02 0.020.02 0.020.02 0.020.02 7. Carbomer7. Carbomer 0.120.12 0.120.12 0.120.12 0.120.12 0.120.12 8. Niacinamide8. Niacinamide -- 2.002.00 -- -- 5.005.00 9. Centella Asiatica9. Centella Asiatica 1.001.00 1.001.00 1.001.00 1.001.00 1.001.00 10. Caprylic/capric triglyceride10. Caprylic/capric triglycerides 5.005.00 5.005.00 5.005.00 5.005.00 5.005.00 11. Squalane11. Squalane 5.005.00 5.005.00 5.005.00 5.005.00 5.005.00 12. Cetearyl alcohol12. Cetearyl alcohol -- 4.004.00 4.004.00 4.004.00 4.004.00 13. C14-22 alcohol13. C14-22 alcohol -- 1.001.00 1.001.00 1.001.00 1.001.00 14. Glyceryl stearate14. Glyceryl stearate 1.001.00 1.001.00 -- 1.001.00 1.001.00 15. PEG 100-stearate15. PEG 100-stearate 1.001.00 1.001.00 -- 1.001.00 1.001.00 16. Alkyl glucoside16. Alkyl glucoside -- 2.002.00 2.002.00 2.002.00 2.002.00 17. Hydrogenated lecithin17. Hydrogenated lecithin -- 0.100.10 0.100.10 0.100.10 0.100.10 18. Preservatives18. Preservatives q.s.q.s. q.s.q.s. q.s.q.s. q.s.q.s. q.s.q.s. 19. Perfume19. Perfume 0.100.10 0.100.10 0.100.10 0.100.10 0.100.10

상기 표 1에서 1 ~ 8은 수용성 성분으로, 이 중 2 ~ 4는 폴리올이고, 5는 pH 조절제이고, 6은 금속봉쇄제이고, 7은 점도 조절제이고, 8은 보조 계면활성제이고, 9는 난용성 유효성분인 센텔라아시아티카며, 10 ~ 17은 유용성 성분으로, 이 중 12, 13는 지방 알코올이고, 14 ~ 17은 계면활성제이며, 18은 보존제이고, 19는 향 성분이다. In Table 1, 1 to 8 are water-soluble components, of which 2 to 4 are polyols, 5 is a pH adjusting agent, 6 is a sequestering agent, 7 is a viscosity adjusting agent, 8 is an auxiliary surfactant, and 9 is an egg. Centella asiatica is a soluble active ingredient, 10 to 17 are oil-soluble ingredients, of which 12 and 13 are fatty alcohols, 14 to 17 are surfactants, 18 are preservatives, and 19 are fragrance ingredients.

센텔라아시아티카와 지방 알코올 및 계면활성제를 포함한 유용성 성분을 혼합하고, 70 ~ 80 ℃에서 가온 용해하여 유상용액을 제조하였다. 별도의 용기에 상기 표 1의 수용성 성분을 혼합하고, 80 ~ 90 ℃에서 가온 용해하여 수상용액을 제조하였다. 상기 유상용액을 상기 수상용액에 천천히 첨가하고 호모믹서로 교반하였다. 상기 교반된 혼합용액을 50 ℃까지 냉각하고 보존제 및 향료를 첨가하고 호모믹서로 교반하였다. 이후 30 ℃까지 급냉한 후 탈포하여, 난용성 물질을 함유하는 일반 수중유 및 액정 에멀젼 화장료 조성물을 제조하였다.An oily solution was prepared by mixing Centella asiatica with oil-soluble components including fatty alcohol and surfactant, and dissolving by heating at 70 ~ 80 °C. An aqueous solution was prepared by mixing the water-soluble components of Table 1 in a separate container and dissolving by heating at 80 to 90 °C. The oil phase solution was slowly added to the aqueous phase solution and stirred with a homomixer. The stirred mixed solution was cooled to 50 °C, a preservative and fragrance were added, and the mixture was stirred with a homomixer. Then, it was rapidly cooled to 30 ° C. and then defoamed to prepare a general oil-in-water and liquid crystal emulsion cosmetic composition containing a sparingly soluble substance.

실험예 1. 입도 분포 측정Experimental Example 1. Measurement of particle size distribution

상기 비교예 1, 및 실시예 1 내지 4의 조성물의 입도 분포를 입도 분석기(LA-960, Horiba, Japan)를 이용하여 제조 직후, 상온 12주, 45℃ 12주, 냉동 12주 후 3회 반복 측정 하여, 평균 값을 계산하였다. 구체적으로, 각 샘플 50 μg을 샘플병에 넣고 증류수로 50배 희석하여 초음파 기기로 5분간 분산한다. 샘플을 입도분석기 사용법에 맞추어 챔버에 천천히 첨가하고, 그 투과도가 80 ~ 90%일 때 측정하여 제조 직후와 냉동 12주 후 입도 변화율을 계산하였다. The particle size distribution of the compositions of Comparative Example 1 and Examples 1 to 4 was repeated three times immediately after preparation using a particle size analyzer (LA-960, Horiba, Japan), room temperature 12 weeks, 45° C. 12 weeks, and freezing 12 weeks. were measured, and the average value was calculated. Specifically, 50 μg of each sample is placed in a sample bottle, diluted 50-fold with distilled water, and dispersed for 5 minutes with an ultrasonic device. The sample was slowly added to the chamber according to the particle size analyzer usage, and the permeability was measured when the transmittance was 80 to 90%, and the particle size change rate was calculated immediately after preparation and after 12 weeks of freezing.

그 결과, 입도 측정 시기에 따른 평균 입도 분포 값을 하기 표 2에 나타내었다. 또한, 비교예 1 및 실시예 1의 제조 직후, 및 냉동 12주 후의 입도 분포도를 도 1에 나타내었다. As a result, the average particle size distribution value according to the particle size measurement time is shown in Table 2 below. In addition, the particle size distribution diagrams immediately after the preparation of Comparative Examples 1 and 1 and after 12 weeks of freezing are shown in FIG. 1 .

비교예 1Comparative Example 1 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4 제조 직후immediately after manufacturing 4.126 μm4.126 μm 9.914 μm9.914 μm 12.750 μm12.750 μm 10.507 μm10.507 μm 6.845 μm6.845 μm 상온 12주room temperature 12 weeks 10.907 μm10.907 μm 10.143 μm10.143 μm 15.133 μm15.133 μm 11.935 μm11.935 μm 7.043 μm7.043 μm 45℃ 12주45℃ 12 weeks 9.032 μm9.032 μm 10.106 μm10.106 μm 13.818 μm13.818 μm 11.264 μm11.264 μm 6.998 μm6.998 μm 냉동 12주frozen 12 weeks 13.322 μm13.322 μm 10.633 μm10.633 μm 16.022 μm16.022 μm 13.414 μm13.414 μm 7.337 μm7.337 μm

그 결과, 도 1 및 상기 표 2에 나타낸 바와 같이, 비교예 1의 조성물은 제조 직후와 비교하여 상온에서 12주 후, 45 ℃에서 12주 후, 또는 냉동에서 12주 후에 입도를 측정한 경우 약 2배 내지 약 3.5배로 증가되어, 입도 분포 값의 변화가 크게 나타난 반면에, 실시예 1 내지 4의 조성물은 제조 직후와 비교하여 상온에서 12주 후, 45 ℃에서 12주 후, 또는 냉동에서 12주 후와 유의적인 차이를 나타내지 않아, 입도 분포 값의 변화가 현저히 적음을 확인할 수 있다.As a result, as shown in FIG. 1 and Table 2, the composition of Comparative Example 1 is about when the particle size is measured after 12 weeks at room temperature, 12 weeks at 45° C., or 12 weeks after freezing compared to immediately after preparation. increased by 2 to about 3.5 times, a large change in the particle size distribution value was shown, whereas the compositions of Examples 1 to 4 were prepared after 12 weeks at room temperature, 12 weeks at 45° C., or 12 weeks at frozen compared to immediately after preparation. Since it does not show a significant difference from the week after week, it can be seen that the change in the particle size distribution value is remarkably small.

이에, 구체적으로 하기 식 1을 이용하여 계산된 입도 변화율을 하기 표 3에 나타내었다.Accordingly, the particle size change rate calculated using Equation 1 below is shown in Table 3 below.

[식 1][Equation 1]

Figure pat00001
Figure pat00001

비교예 1Comparative Example 1 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4 상온 12주room temperature 12 weeks 164.35%164.35% 2.31%2.31% 18.69%18.69% 13.59%13.59% 2.89%2.89% 45℃ 12주45℃ 12 weeks 118.90%118.90% 1.94%1.94% 8.38%8.38% 7.20%7.20% 2.24%2.24% 냉동 12주frozen 12 weeks 222.88%222.88% 7.25%7.25% 25.66%25.66% 27.67%27.67% 7.19%7.19%

그 결과, 상기 표 3에 나타낸 바와 같이, 비교예 1의 조성물은 매우 높은 입도 변화율을 나타내었으나, 실시예 1 내지 4의 조성물은 현저히 낮은 수준의 입도 변화율을 나타내었다. 특히, 보조 계면활성제로서 나이아신아미드를 더 포함하는 실시예 1 및 4의 조성물은 실시예 2 및 3의 조성물과 비교해서도 낮은 입도 변화율을 나타내었다.As a result, as shown in Table 3, the composition of Comparative Example 1 exhibited a very high rate of change in particle size, but the compositions of Examples 1 to 4 exhibited a significantly lower rate of change in particle size. In particular, the compositions of Examples 1 and 4 further comprising niacinamide as an auxiliary surfactant showed a lower particle size change rate compared to the compositions of Examples 2 and 3.

상기 결과로부터, 실시예 1 내지 4의 조성물은 지방 알코올, 스테아레이트계 계면활성제, 글루코사이드계 계면활성제, 소르비탄계 계면활성제를 포함하고, 특히 실시예 1 및 4의 조성물은 보조 계면활성제를 더 포함함으로써, 상기 조성물은 상온, 고온, 냉동 보관 후에도 입도 변화를 나타내지 않으므로, 난용성 물질인 센텔라아시아티카의 제형 내 안정성이 현저히 개선된 것임을 확인할 수 있다.From the above results, the compositions of Examples 1 to 4 include fatty alcohol, a stearate-based surfactant, a glucoside-based surfactant, and a sorbitan-based surfactant, and in particular, the compositions of Examples 1 and 4 further include an auxiliary surfactant By doing so, since the composition does not show a change in particle size even after storage at room temperature, high temperature, or frozen, it can be confirmed that the stability in the formulation of Centella asiatica, a sparingly soluble material, is significantly improved.

실험예 2. 석출 및 광택 확인Experimental Example 2. Confirmation of precipitation and gloss

비교예 1, 및 실시예 1 내지 4의 조성물 내 난용성 물질의 제형 내 안정성을 평가하기 위해, 석출 현상 및 광택 정도를 평가하였다. 석출에 대한 평가 기준은 다음과 같다: ○: 석출 있음; △: 표면 불안정; X: 석출 없음. 광택 정도에 대한 평가 기준은 다음과 같다: ○: 광택 있음; △: 표면 불안정; X: 광택 없음. 평가 결과는 하기 표 4에 나타내었다.In order to evaluate the stability in the formulation of the composition of Comparative Example 1 and Examples 1 to 4 of the sparingly soluble material, the precipitation phenomenon and the glossiness were evaluated. The evaluation criteria for precipitation are as follows: ○: with precipitation; △: surface instability; X: No precipitation. Evaluation criteria for the degree of gloss are as follows: ○: glossy; △: surface instability; X: No gloss. The evaluation results are shown in Table 4 below.

실험항목Experimental items 비교예 1Comparative Example 1 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4 석출precipitation 제조직후immediately after manufacturing XX XX XX XX XX 상온 12주room temperature 12 weeks OO XX XX XX 45℃ 12주45℃ 12 weeks XX XX XX XX XX 냉동 12주frozen 12 weeks OO XX XX 광택Polish 제조직후immediately after manufacturing OO OO OO OO OO 상온 12주room temperature 12 weeks OO OO 45℃ 12주45℃ 12 weeks OO OO OO OO 냉동 12주frozen 12 weeks OO XX OO

그 결과, 상기 표 4에 나타낸 바와 같이, 비교예 1의 조성물은 상온 12주 및 냉동 12주 후에 석출 현상이 나타난 반면에, 실시예 1 내지 4의 조성물은 상온 12주, 45 ℃ 12주, 및 냉동 12주 후에 석출 현상이 거의 나타나지 않았으며, 특히, 보조 계면활성제를 더 포함하는 실시예 1 및 4의 조성물은 보관 기간 및 온도와 무관하게 석출 현상이 일체 나타나지 않았다. As a result, as shown in Table 4, the composition of Comparative Example 1 showed a precipitation phenomenon after 12 weeks at room temperature and 12 weeks at room temperature, whereas the compositions of Examples 1 to 4 showed 12 weeks at room temperature, 12 weeks at 45 °C, and Precipitation phenomenon was hardly observed after 12 weeks of freezing, and in particular, the compositions of Examples 1 and 4 further comprising an auxiliary surfactant did not exhibit any precipitation phenomenon regardless of the storage period and temperature.

또한, 비교예 1의 조성물은 상온 12주, 45 ℃ 12주, 및 냉동 12주 후에 표면이 불안정하고, 광택을 나타내지 않았으나, 실시예 1 내지 4의 조성물 중에서도 보조 계면활성제를 더 포함하는 실시예 1 및 4의 조성물은 보관 기간 및 온도와 무관하게 광택을 나타내었다.In addition, the composition of Comparative Example 1 had an unstable surface and did not show gloss after 12 weeks at room temperature, 12 weeks at 45°C, and 12 weeks at 45°C, but Example 1 further comprising an auxiliary surfactant among the compositions of Examples 1 to 4 And the composition of 4 showed gloss regardless of the storage period and temperature.

상기 결과로부터, 실시예 1 내지 4의 조성물은 지방 알코올, 스테아레이트계 계면활성제, 글루코사이드계 계면활성제, 소르비탄계 계면활성제를 포함하고, 특히 실시예 1 및 4의 조성물은 보조 계면활성제를 더 포함함으로써, 상온, 고온, 냉동 보관 후에도 석출 현상이 나타나지 않고, 광택 정도를 유지하므로, 난용성 물질인 센텔라아시아티카의 제형 내 안정성이 현저히 개선된 것임을 확인할 수 있다.From the above results, the compositions of Examples 1 to 4 include fatty alcohol, a stearate-based surfactant, a glucoside-based surfactant, and a sorbitan-based surfactant, and in particular, the compositions of Examples 1 and 4 further include an auxiliary surfactant By doing so, it can be confirmed that the precipitation phenomenon does not appear even after storage at room temperature, high temperature, and frozen, and the gloss level is maintained, so that the stability in the formulation of Centella asiatica, which is a poorly soluble material, is remarkably improved.

실험예 3. 점도 측정Experimental Example 3. Viscosity Measurement

비교예 1, 및 실시예 1 내지 4의 조성물의 점도를 점도계(DV2T-LV, Brookfield, Canada)를 이용하여 제조 직후, 상온 12주, 45℃ 12주, 및 냉동 12주 후에 측정하였다. 구체적으로, 점도에 따라 63, 64번 회전심봉을 샘플에 접촉한 상태로 회전속도 10 ~ 15 rpm의 범위 내에서 점도를 측정하였다. 그 결과, 점도 측정 시기에 따른 점도 값을 하기 표 5에 나타내었다.The viscosity of the compositions of Comparative Example 1 and Examples 1 to 4 was measured using a viscometer (DV2T-LV, Brookfield, Canada) immediately after preparation, room temperature 12 weeks, 45° C. 12 weeks, and freezing 12 weeks. Specifically, the viscosity was measured within a rotational speed of 10 to 15 rpm in a state in which the 63 and 64 rotating mandrels were in contact with the sample according to the viscosity. As a result, the viscosity values according to the viscosity measurement time are shown in Table 5 below.

점도측정Viscosity measurement 비교예 1Comparative Example 1 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4 제조 직후immediately after manufacturing 3,740 cP3,740 cP 32,700 cP32,700 cP 33,450 cP33,450 cP 28,800 cP28,800 cP 25,400 cP25,400 cP 상온 12주room temperature 12 weeks 5,770 cP5,770 cP 33,700 cP33,700 cP 39,750 cP39,750 cP 33,700 cP33,700 cP 25,950 cP25,950 cP 45℃ 12주45℃ 12 weeks 6,120 cP6,120 cP 33,800 cP33,800 cP 35,900 cP35,900 cP 30,500 cP30,500 cP 26,050 cP26,050 cP 냉동 12주frozen 12 weeks 7,320 cP7,320 cP 33,850 cP33,850 cP 42,050 cP42,050 cP 34,950 cP34,950 cP 26,400 cP26,400 cP

그 결과, 상기 표 5에 나타낸 바와 같이, 비교예 1의 조성물은 상온 12주, 45℃ 12주, 및 냉동 12주 후의 점도 변화가 100% 이상으로 점도 변화가 매우 큰 반면에, 실시예 1 내지 4의 조성물은 현저히 낮은 수준의 점도 변화율을 나타내었다. 특히, 보조 계면활성제로서 나이아신아미드를 더 포함하는 실시예 1 및 4의 조성물은 실시예 2 및 3의 조성물과 비교해서도 5 내지 10%의 낮은 점도 변화율을 나타내었다.As a result, as shown in Table 5, the composition of Comparative Example 1 had a very large viscosity change of 100% or more after 12 weeks at room temperature, 12 weeks at 45°C, and 12 weeks at 45° C., whereas Examples 1 to The composition of 4 showed a significantly lower level of viscosity change. In particular, the compositions of Examples 1 and 4 further comprising niacinamide as an auxiliary surfactant showed a low viscosity change rate of 5 to 10% compared to the compositions of Examples 2 and 3 as well.

상기 결과로부터, 실시예 1 내지 4의 조성물은 지방 알코올, 스테아레이트계 계면활성제, 글루코사이드계 계면활성제, 소르비탄계 계면활성제를 포함하고, 특히 실시예 1 및 4의 조성물은 보조 계면활성제를 더 포함함으로써, 상온, 고온, 냉동 보관 후에도 낮은 점도 변화를 나타내므로, 난용성 물질인 센텔라아시아티카의 제형 내 안정성이 현저히 개선된 것임을 확인할 수 있다.From the above results, the compositions of Examples 1 to 4 include fatty alcohol, a stearate-based surfactant, a glucoside-based surfactant, and a sorbitan-based surfactant, and in particular, the compositions of Examples 1 and 4 further include an auxiliary surfactant By doing so, it can be confirmed that the stability in the formulation of Centella asiatica, which is a sparingly soluble substance, is remarkably improved because it shows a low viscosity change even after storage at room temperature, high temperature, and frozen.

실험예 4. 피부 모사 구조 분석Experimental Example 4. Analysis of skin-simulating structure

실시예 1의 조성물 내 난용성 물질의 제형 내 안정성을 평가하기 위해, 제조 직후 및 냉동 12주 후의 피부 모사 구조를 편광 현미경을 통해 관찰하고, 소각 X선 산란 피크의 비율을 분석하였다. 브래그 스페이싱 비율(Bragg spacing ratio)에 따르면 소각 X선 산란 피크의 비율이 1: 2: 3으로 나타날 때, 라멜라 구조로 볼 수 있다. In order to evaluate the stability in the formulation of the poorly soluble material in the composition of Example 1, the structure of the skin mimicked immediately after preparation and 12 weeks after freezing was observed through a polarizing microscope, and the ratio of small-angle X-ray scattering peaks was analyzed. According to the Bragg spacing ratio, when the ratio of small-angle X-ray scattering peaks is 1: 2: 3, it can be seen as a lamellar structure.

그 결과, 도 2에 나타낸 바와 같이, 실시예 1의 조성물은 안정한 다층 라멜라 구조를 갖는 액정 에멀젼이고, 제조 직후와 냉동에서 12주 동안 보관한 후에도 액정상이 생성 및 유지됨을 확인하였다. As a result, as shown in FIG. 2, the composition of Example 1 was a liquid crystal emulsion having a stable multilayer lamellar structure, and it was confirmed that the liquid crystal phase was generated and maintained immediately after preparation and after storage for 12 weeks in the freezer.

또한, 도 3에 나타낸 바와 같이, 실시예 1의 조성물의 제조 직후 및 냉동 12주 후의 소각 X선 산란분석 그래프를 분석해보면, 제조 직후 q 값의 비가 0.0296: 0.0592: 0.0888 (약 1: 2: 3)으로 라멜라 구조임을 확인하였고, 냉동 12주 후에도 0.0250: 0.0500: 0.0750 (약 1: 2: 3)으로 라멜라 구조임을 확인하였다.In addition, as shown in FIG. 3, when analyzing the graph of small-angle X-ray scattering analysis immediately after preparation of the composition of Example 1 and 12 weeks after freezing, the ratio of q values immediately after preparation is 0.0296: 0.0592: 0.0888 (about 1: 2: 3 ) was confirmed to have a lamellar structure, and even after 12 weeks of freezing, 0.0250: 0.0500: 0.0750 (about 1: 2: 3) was confirmed to have a lamellar structure.

상기 결과로부터, 실시예 1의 조성물은 지방 알코올, 스테아레이트계 계면활성제, 글루코사이드계 계면활성제, 소르비탄계 계면활성제, 및 보조 계면활성제를 포함함으로써, 냉동 장기보관 후에도 구조의 변화 없이 피부모사구조를 유지할 수 있음을 확인할 수 있다.From the above results, the composition of Example 1 contains a fatty alcohol, a stearate-based surfactant, a glucoside-based surfactant, a sorbitan-based surfactant, and an auxiliary surfactant. can confirm that it can be maintained.

Claims (8)

난용성 물질, 지방 알코올, 계면활성제, 및 보조 계면활성제를 포함하는 화장료 조성물.A cosmetic composition comprising a sparingly soluble substance, a fatty alcohol, a surfactant, and an auxiliary surfactant. 청구항 1에 있어서, 상기 난용성 물질은 센텔라아시아티카인 것인 화장료 조성물.The cosmetic composition according to claim 1, wherein the sparingly soluble substance is Centella asiatica. 청구항 1에 있어서, 상기 지방 알코올은 스테아릴 알코올, 세틸 알코올, 세테아릴 알코올, 미리스틸 알코올, 카프릴릭 알코올, 라우릴 알코올, 데실 알코올, 올레일 알코올, 또는 이들의 조합인 것인 화장료 조성물.The cosmetic composition according to claim 1, wherein the fatty alcohol is stearyl alcohol, cetyl alcohol, cetearyl alcohol, myristyl alcohol, caprylic alcohol, lauryl alcohol, decyl alcohol, oleyl alcohol, or a combination thereof. . 청구항 1에 있어서, 상기 계면활성제는 스테아레이트계 계면활성제, 글루코사이드계 계면활성제, 소르비탄계 계면활성제 또는 이들의 조합인 것인 화장료 조성물.The cosmetic composition of claim 1, wherein the surfactant is a stearate-based surfactant, a glucoside-based surfactant, a sorbitan-based surfactant, or a combination thereof. 청구항 1에 있어서, 상기 보조 계면활성제는 니아신아미드(Niacinamide), 우레아(Urea), N,N-디에틸니코틴아미드(N,N-diethylnicotinamide), 폴리에틸렌글리콜-블록-폴리프로필렌글리콜(PEG-b-PPG), 폴리카프로락톤-블록-폴리에틸렌글리콜(PCL-b-PEG), 폴리프로필렌글리콜-블록-폴리카프로락톤(PPG-b-PCL), 폴리에틸렌글리콜-블록-폴리프로필렌글리콜-블록-폴리에틸렌글리콜(PEG-b-PPG-b-PEG), 폴리에틸렌글리콜-블록-폴리카프로락톤-블록-폴리에틸렌글리콜(PEG-b-PCL-b-PEG), 폴리카프로락톤-블록-폴리에틸렌글리콜-블록-폴리카프로락톤(PCL-b-PEG-b-PCL), 폴리프로필렌글리콜-블록-폴리카프로락톤-블록-폴리프로필렌글리콜(PPG-b-PCL-b-PPG), 폴리카프로락톤-블록-폴리프로필렌글리콜-블록폴리카프로락톤(PCL-b-PPG-b-PCL), 또는 이들의 조합인 것인 화장료 조성물.The method according to claim 1, wherein the auxiliary surfactant is niacinamide (Niacinamide), urea (Urea), N,N- diethylnicotinamide (N,N-diethylnicotinamide), polyethylene glycol-block- polypropylene glycol (PEG-b- PPG), polycaprolactone-block-polyethylene glycol (PCL-b-PEG), polypropylene glycol-block-polycaprolactone (PPG-b-PCL), polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol ( PEG-b-PPG-b-PEG), polyethylene glycol-block-polycaprolactone-block-polyethylene glycol (PEG-b-PCL-b-PEG), polycaprolactone-block-polyethylene glycol-block-polycaprolactone (PCL-b-PEG-b-PCL), polypropylene glycol-block-polycaprolactone-block-polypropylene glycol (PPG-b-PCL-b-PPG), polycaprolactone-block-polypropylene glycol-block Polycaprolactone (PCL-b-PPG-b-PCL), or a cosmetic composition of a combination thereof. 청구항 1에 있어서, 조성물 총 중량 대비, 난용성 물질 0.001 내지 10 중량%, 지방 알코올 0.1 내지 10 중량%, 계면활성제 0.1 내지 10 중량%, 보조 계면활성제 0.1 내지 10 중량%를 포함하는 화장료 조성물.The cosmetic composition of claim 1, wherein the composition comprises 0.001 to 10% by weight of a sparingly soluble substance, 0.1 to 10% by weight of a fatty alcohol, 0.1 to 10% by weight of a surfactant, and 0.1 to 10% by weight of an auxiliary surfactant, based on the total weight of the composition. 청구항 1에 있어서, 상기 조성물의 제조 직후의 점도 또는 입도와 비교하여, 1일 내지 20주 동안 보관한 후의 점도 또는 입도의 변화율이 1 내지 10%인 것인 화장료 조성물.The cosmetic composition according to claim 1, wherein the rate of change in viscosity or particle size after storage for 1 to 20 weeks is 1 to 10% compared to the viscosity or particle size immediately after preparation of the composition. 청구항 1에 있어서, 다층 라멜라 구조를 갖는 액정 에멀젼 제형인 화장료 조성물.The cosmetic composition according to claim 1, which is a liquid crystal emulsion formulation having a multilayer lamellar structure.
KR1020190164798A 2019-12-11 2019-12-11 Cosmetic composition for stabilizing poorly soluble materials KR102294985B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1020190164798A KR102294985B1 (en) 2019-12-11 2019-12-11 Cosmetic composition for stabilizing poorly soluble materials
PCT/KR2020/014419 WO2021118044A1 (en) 2019-12-11 2020-10-21 Cosmetic composition for stabilizing poorly soluble material
KR1020210106951A KR102322172B1 (en) 2019-12-11 2021-08-12 Cosmetic composition for stabilizing poorly soluble materials
KR1020210110343A KR102322173B1 (en) 2019-12-11 2021-08-20 Cosmetic composition for stabilizing poorly soluble materials

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190164798A KR102294985B1 (en) 2019-12-11 2019-12-11 Cosmetic composition for stabilizing poorly soluble materials

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020210106951A Division KR102322172B1 (en) 2019-12-11 2021-08-12 Cosmetic composition for stabilizing poorly soluble materials
KR1020210110343A Division KR102322173B1 (en) 2019-12-11 2021-08-20 Cosmetic composition for stabilizing poorly soluble materials

Publications (3)

Publication Number Publication Date
KR20210073957A true KR20210073957A (en) 2021-06-21
KR102294985B1 KR102294985B1 (en) 2021-08-30
KR102294985B9 KR102294985B9 (en) 2022-07-11

Family

ID=76329417

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020190164798A KR102294985B1 (en) 2019-12-11 2019-12-11 Cosmetic composition for stabilizing poorly soluble materials
KR1020210106951A KR102322172B1 (en) 2019-12-11 2021-08-12 Cosmetic composition for stabilizing poorly soluble materials
KR1020210110343A KR102322173B1 (en) 2019-12-11 2021-08-20 Cosmetic composition for stabilizing poorly soluble materials

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020210106951A KR102322172B1 (en) 2019-12-11 2021-08-12 Cosmetic composition for stabilizing poorly soluble materials
KR1020210110343A KR102322173B1 (en) 2019-12-11 2021-08-20 Cosmetic composition for stabilizing poorly soluble materials

Country Status (2)

Country Link
KR (3) KR102294985B1 (en)
WO (1) WO2021118044A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102506124B1 (en) * 2021-12-30 2023-03-08 한국콜마주식회사 cosmetic composition having excellent stabilizing poorly soluble materials and skin permeability

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102609651B1 (en) * 2023-08-08 2023-12-06 한국콜마주식회사 Method for stabilizing poorly soluble materials through the clathrate effect of cross-linked hyaluronic acid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150092102A (en) * 2012-10-12 2015-08-12 로레알 Cosmetic compositions containing at least one hydrotrope and at least one active compound
KR20190043307A (en) * 2017-10-18 2019-04-26 진성현 core-shell capsule including active ingredients and manufacturing method thereof and cosmetic composition including the same
KR20190106702A (en) * 2019-02-25 2019-09-18 코스맥스 주식회사 Multilamellar Emulsion Cosmetic Composition Comprising Natural Ceramide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150116655A (en) * 2014-04-08 2015-10-16 주식회사 엘지생활건강 Cosmetic composition stabilizing insoluble functional ingredient
KR102002283B1 (en) * 2017-09-05 2019-07-23 코스맥스 주식회사 Composition comprising eutectic mixture of extract of centella asiatica

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150092102A (en) * 2012-10-12 2015-08-12 로레알 Cosmetic compositions containing at least one hydrotrope and at least one active compound
KR20190043307A (en) * 2017-10-18 2019-04-26 진성현 core-shell capsule including active ingredients and manufacturing method thereof and cosmetic composition including the same
KR20190106702A (en) * 2019-02-25 2019-09-18 코스맥스 주식회사 Multilamellar Emulsion Cosmetic Composition Comprising Natural Ceramide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102506124B1 (en) * 2021-12-30 2023-03-08 한국콜마주식회사 cosmetic composition having excellent stabilizing poorly soluble materials and skin permeability

Also Published As

Publication number Publication date
KR102294985B1 (en) 2021-08-30
KR20210104616A (en) 2021-08-25
KR102322173B1 (en) 2021-11-05
WO2021118044A1 (en) 2021-06-17
KR102322172B1 (en) 2021-11-05
KR20210108927A (en) 2021-09-03
KR102294985B9 (en) 2022-07-11

Similar Documents

Publication Publication Date Title
RU2459613C2 (en) Oil-in-water emulsion composition and method for preparing it
KR102322173B1 (en) Cosmetic composition for stabilizing poorly soluble materials
KR100861980B1 (en) Encapsulated composition of a non-water liquid crystalline phase having skin analogue membrane, their cosmetic compositions, and manufacturing method thereof
KR101629778B1 (en) Highly transparent emulsion composition and highly transparent cosmetic
KR101934788B1 (en) Cosmetic composition of oil in water emulsion type using glycolipid-based emulsifier from microorganism and manufacturing method thereof
EP1380278A1 (en) Cosmetic emulsion preparation and agent for external use
KR20150034451A (en) A preparation method of multilamellar liquid crystal emulsions including intercellular lipids
Tasic‐Kostov et al. Lactobionic acid as antioxidant and moisturizing active in alkyl polyglucoside‐based topical emulsions: the colloidal structure, stability and efficacy evaluation
KR101868726B1 (en) Method for producing ceramide dispersion composition
KR101981068B1 (en) Foam Type Mask Pack Containing Liquid Crystal Composition and Method for Preparing Same
KR20170123612A (en) Composition for nanoemulsion emulsification, bicontinuous microemulsion, cosmetic, and method for producing same
KR102181475B1 (en) Composition for stabilizing insoluble ingredient and cosmetic composition containing the same
CN109414390B (en) External preparation for skin
JPH06345633A (en) External preparation for skin
KR102506722B1 (en) Water-in-oil-in-water type multiple emulsion for cosmetic composition with low viscosity
KR20210119781A (en) Cosmetic composition of water-in-oil type (W/O) Lamellar liquid crystalline emulsion
KR101264902B1 (en) Cosmetic composition in the form of liquid crystal emulsion
KR101868481B1 (en) Cosmetic composition for moisturizing skin with snowflake pattern and method of thereof
KR100789628B1 (en) Capsule Containing Retinoid to be Easily Absorbed by Skin , Method for Preparing the Capsule, Cosmetic Composition Having Anti-Wrinkle Effect Containing the Capsule, and Method for Preparing the Composition
Filipović et al. Feasibility of a natural surfactant as a stabilizer for cosmetics with liposome-encapsulated plant stem cells: pre-formulation and formulation through stability studies
KR102309639B1 (en) Oil-in-water nano emulsion cosmetic composition containing high content oil
KR20070089302A (en) Transparent oil in water type emulsified cosmetic compositions
KR20230021435A (en) Oil-in-water cosmetic composition comprising nanovesicles in which poorly soluble ingredients are stabilized
KR20180032842A (en) Cosmetic composition comprising cubosome containing active ingredient
KR20170094848A (en) Composition of non-water liquid crystalline phase comprising ceramide and Method thereof

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
Z072 Maintenance of patent after cancellation proceedings: certified copy of decision transmitted [new post grant opposition system as of 20170301]
Z131 Decision taken on request for patent cancellation [new post grant opposition system as of 20170301]